Recce Pharmaceuticals up 6% on new antibiotic production milestone
Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
ASR | Ann: ASR NTA 24-04-2024 $6.49581 | 26/04/24 | 0 | 26 | |||
|
|||||||
ASR | Ann: ASR NTA 23-04-2024 $6.48644 | 24/04/24 | 0 | 34 | |||
|
|||||||
ASR | Ann: ASR NTA 22-04-2024 $6.51787 | 23/04/24 | 0 | 36 | |||
|
|||||||
ASR | Ann: ASR NTA 19-04-2024 $6.47478 | 22/04/24 | 0 | 54 | |||
|
|||||||
ASR | Ann: ASR NTA 18-04-2024 $6.53738 | 19/04/24 | 0 | 35 | |||
|
|||||||
ASR | Ann: ASR NTA 17-04-2024 $6.48300 | 18/04/24 | 0 | 47 | |||
|
|||||||
ASR | Ann: ASR NTA 16-04-2024 $6.52089 | 17/04/24 | 0 | 31 | |||
|
|||||||
ASR | Ann: ASR NTA 15-04-2024 $6.63929 | 16/04/24 | 0 | 40 | |||
|
See All Discussions